Evidence map›Paper›PMID 34521190›Full record

ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2021

[Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib: 
A Case Report and Literature Review].

Haixiang Yang, Wei Zhu

Open access · greenAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Haixiang YangDepartment of Oncology, Baotou Central Hospital, Baotou 014040, China.
Wei ZhuDepartment of Oncology, Baotou Central Hospital, Baotou 014040, China.
Baotou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
.

Indexed as

Anaplastic Lymphoma KinaseAntineoplastic AgentsCarbazolesCarcinoma, Non-Small-Cell LungLung NeoplasmsPiperidinesProtein Kinase InhibitorsHumansMutationPleural NeoplasmsRetrospective StudiesTomography, X-Ray ComputedalectinibALK protein, humanAnaplastic Lymphoma KinaseAntineoplastic AgentsCarbazolesPiperidinesProtein Kinase InhibitorsAlectinibAnaplastic lymphoma kinaseLung neoplasmsSide effects

Identifiers

PMID34521190
PMCPMC8503986
OpenAlexW3199005851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.